Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 7/20 | 0.42 |
| ▸ | DRD4 | P21917 | 7/20 | 0.42 |
| ▸ | DRD3 | P35462 | 7/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456913 | 0.93 | TLR8 (0.42) | TLR8TLR7NUDT1DRD2DRD4 | |
| SCHEMBL1456937 | 0.90 | TLR8 (0.47) | TLR8TLR7NUDT1 | |
| SCHEMBL1456861 | 0.90 | TLR8 (0.60) | TLR8TLR7NUDT1 | |
| SCHEMBL1457538 | 0.89 | TLR7 (0.47) | TLR8TLR7NUDT1MAPT | |
| SCHEMBL1457535 | 0.83 | TLR7 (0.44) | TLR8TLR7NUDT1 | |
| SCHEMBL1456656 | 0.83 | TLR8 (0.54) | TLR8TLR7NUDT1 | |
| SCHEMBL1456987 | 0.82 | TLR7 (0.42) | TLR8TLR7NUDT1 | |
| SCHEMBL1456868 | 0.80 | TLR8 (0.61) | TLR8TLR7NUDT1 | |
| SCHEMBL1456611 | 0.79 | TLR7 (0.48) | TLR8TLR7NUDT1 | |
| SCHEMBL1456682 | 0.79 | TLR7 (0.45) | TLR8TLR7DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915281-B2 | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| US-20070287725-A1 | Isoxazole, Dihydroisoxazole, And Oxadiazole Substituted Imidazo Ring Compounds And Method | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-12-13 | — | — | US | disclosed |
| WO-2006065280-A2 | ISOXAZOLE, DIHYDROISOXAZOLE, AND OXADIAZOLE SUBSTITUTED IMIDAZO RING COMPOUNDS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287725-A1 | Isoxazole, Dihydroisoxazole, And Oxadiazole Substituted Imidazo Ring Compounds And Method | IFNG, IL4, IL2 | TLR8 541/4885TLR7 137/4885NUDT1 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.